Blueprint Medicines Priced, Nasdaq: BPMC

Preclinical biotech developing kinase inhibitors for cancer and genetic diseases.

Industry: Health Care

Latest Trade: $52.26 0.00 (0.0%)

First Day Return: +4.8%

Return from IPO: +190.3%

Industry: Health Care

We are a biopharmaceutical company focused on improving the lives of patients with genomically defined diseases driven by abnormal kinase activation. Our approach is to systematically and reproducibly identify kinases that are drivers of genomically defined diseases and to craft drug candidates with therapeutic windows that provide significant and durable clinical responses to patients. This integrated biology and chemistry approach enables us to drug known kinases that have been difficult to inhibit selectively and also identify, characterize and drug novel kinase targets. By focusing on genomically defined diseases, we believe that we will have a more efficient development path with a greater likelihood of success. Over the past three years, we have developed a robust small molecule drug pipeline in cancer and a rare genetic disease. One of our lead drug candidates is BLU-285, which targets KIT Exon 17 and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. BLU-285 will initially be developed for patients with systemic mastocytosis, a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor, the most common sarcoma, or tumor of bone or connective tissue, of the gastrointestinal tract. Our other lead drug candidate is BLU-554, which targets FGFR4, a kinase that is aberrantly activated and is a driver of disease in a defined subset of patients with hepatocellular carcinoma, the most common type of liver cancer. Both drug candidates have demonstrated proof of concept in pre-clinical models and we expect to file INDs in mid-2015 and initiate our Phase 1 clinical trials in mid-2015.
more less
IPO News for Blueprint Medicines
more
IPO Data
IPO File Date 03/23/2015
Offer Price $18.00
Price Range $15.00 - $17.00
Offer Shares (mm) 8.1
Deal Size ($mm) $147
IPO Data
IPO Date 04/29/2015
Offer Price $18.00
Price Range $15.00 - $17.00
Offer Shares (mm) 8.1
Deal Size ($mm) $147
Underwriters
more
Company Data
Headquarters Cambridge, MA
Founded 2008
Employees 60
Website www.blueprintmedicines.com